The trial, sponsored by Peking University, aims to evaluate the safety of PD-1 knockout engineered T cells in patients with metastatic renal cell carcinoma (RCC) who have progressed after standard treatments. Given the increasing interest in immunotherapies and CAR-T cell therapies, this asset could represent a novel approach in a competitive landscape dominated by existing therapies such as checkpoint inhibitors. However, the trial has been withdrawn due to lack of funding, which raises concerns about the viability of further development and potential market entry. The RCC market is projected to grow, driven by advancements in immunotherapy, but the absence of funding may hinder this asset's progress.